Previous 10 | Next 10 |
Supernus Pharmaceuticals (SUPN) says it received a complete response letter regarding its new drug application for SPN-812 for the treatment of ADHD in pediatric patients 6-17 years old.The FDA says the application is not ready for approval in its present form, citing Superna's in-house labor...
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine...
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2020 Earnings Conference Call November 04, 2020, 9:00 AM ET Company Participants Peter Vozzo - IR, Westwicke Jack Khattar - President and Chief Executive Officer Gregory Patrick - Retiring Chief Financial Officer James Kelly - New Chief Financial Offic...
Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q3 2020 Earnings Call Nov 4, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Trans...
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...
Gainers: Biogen (BIIB) +43%, Digirad (DRAD) +28%, Supernus Pharmaceuticals (SUPN) +21%, Jupiter Wellness (JUPW) +3%, Cassava Sciences (SAVA) +13%.Losers: Repro Med Systems (KRMD) -28%, Aptevo Therapeutics (APVO) -13%, Allogene Therapeutics (AL...
Gainers: [[DRAD]] +40.0%. [[SUPN]] +17.8%. [[SMCI]] +13.2%. [[ITUB]] +6.7%. [[KE]] +6.2%.Losers: [[NBR]] -12.8%. [[TRHC]] -8.6%. [[MRCY]] -7.4%. [[CLW]] -6.6%. [[CARG]] -5.5%. For further details see: DRAD, SUPN, NBR and CLW among after-hours movers
Supernus Pharmaceuticals (SUPN): Q3 GAAP EPS of $0.74 beats by $0.47.Revenue of $155.14M (+51.9% Y/Y) beats by $24.38M.Raises 2020 Guidance: Net product sales increased to $500-$525M from $460-500M, and operating earnings of $145-$160M from $90-110M.Shares +6.67%.Press Release For further d...
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 million Q3 2020 operating earnings of $56.1 million On track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDA Topline data from ...
Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, after market close.The consensus EPS Estimate is $0.27 (-50.0% Y/Y) and the consensus Revenue Estimate is $130.76M (+28.0% Y/Y).Over the last 2 years, SUPN has beaten EPS estimates 75...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial ...
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...